The FDA has approved Symbravo, a novel combination of rizatriptan (a triptan) and meloxicam (a nonsteroidal anti-inflammatory drug), developed by Axsome Therapeutics, for the acute treatment of migraine with or without aura in adults. This approval offers a new hope for patients who experience inadequate relief from currently available migraine medicati…
